BRIM Biotechnology Inc.
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing B… Read more
BRIM Biotechnology Inc. (6885) - Total Liabilities
Latest total liabilities as of June 2024: NT$25.06 Million TWD
Based on the latest financial reports, BRIM Biotechnology Inc. (6885) has total liabilities worth NT$25.06 Million TWD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BRIM Biotechnology Inc. - Total Liabilities Trend (2019–2023)
This chart illustrates how BRIM Biotechnology Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BRIM Biotechnology Inc. Competitors by Total Liabilities
The table below lists competitors of BRIM Biotechnology Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Anderson Industrial Corp
TW:1528
|
Taiwan | NT$3.22 Billion |
|
Smartbroker Holding AG
XETRA:SB1
|
Germany | €11.54 Million |
|
Lechwerke AG
F:LEC
|
Germany | €1.18 Billion |
|
Safkar Ege Sogutmacilik Klima Soguk Hava Tesisleri Ihracat Ithalat Sanayi ve Tic
IS:SAFKR
|
Turkey | TL491.99 Million |
|
Prairie Operating Co. Common Stock
OTCQB:PROP
|
USA | $764.37 Million |
Liability Composition Analysis (2019–2023)
This chart breaks down BRIM Biotechnology Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 63.15 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.02 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.02 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BRIM Biotechnology Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BRIM Biotechnology Inc. (2019–2023)
The table below shows the annual total liabilities of BRIM Biotechnology Inc. from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | NT$42.16 Million | +66.65% |
| 2022-12-31 | NT$25.30 Million | +44.15% |
| 2021-12-31 | NT$17.55 Million | -67.17% |
| 2020-12-31 | NT$53.46 Million | +235.16% |
| 2019-12-31 | NT$15.95 Million | -- |